SCHEMBL4748830

SCHEMBL4748830

Cc1ccc(-c2cc(Cl)nc(C)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
KDM4E B2RXH2 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 2/20 0.55
HPGD P15428 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TP53 P04637 3/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.46
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
CXCL12 P48061 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
AGTR1 P30556 1/20 0.42
DHODH Q02127 1/20 0.42
KMO O15229 1/20 0.41
SHMT2 P34897 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12264966 0.85 MAPT (0.59) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL600729 0.85 RAD51 (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL25068057 0.85 KDM4E (0.58) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL3450627 0.84 KDM4E (0.70) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL602093 0.84 KDM4E (0.61) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL17412398 0.84 MEN1 (0.55) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL10685624 0.82 GSK3B (0.46) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL1013065 0.82 ALDH1A1 (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL9013572 0.82 KDM4E (0.53) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL3451558 0.81 HSP90AB1 (0.68) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008110891-A2 NEW HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED, (IN) 2008-09-18 WO disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed
EP-0020298-B1 BENZOXAZOLYL STILBENES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS OPTICAL BRIGHTENERS FOR ORGANIC MATERIALS CIBA-GEIGY AG (CH) 1983-06-22 EP disclosed
US-4297234-A OPTICAL BRIGHTENERS CIBA-GEIGY CORPORATION (US) 1981-10-27 US disclosed
EP-0020298-A1 Benzoxazolyl stilbenes, process for their preparation and their use as optical brighteners for organic materials CIBA-GEIGY AG (CH) 1980-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221103-A1 New heterocyclic compounds LOXL4, CXCR4, LTC4S MAPT 699/4885KDM4E 1998/4885MEN1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.